Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT04870580
Overview
[18F]fluorodopa (3, 4-dihydroxy-6-[18F]fluoro-L-phenylalanine/ FDOPA) is an amino acid PET tracer originally developed for brain imaging in patients with movement disorders but has been found to be useful in brain tumour imaging. [18F]fluorodopa has been demonstrated to be predominantly transported by the L-type amino acid transporter without significant uptake into surrounding normal brain parenchyma with the exception of the basal ganglia. Assessing the feasibility of performing PET guided histopathology in a single and multi-site setting will be crucial in order to use PET as a planning tool for brain biopsy to detect high-grade transformation in low-grade gliomas.
Sponsor
University College, London
Phase
N/A
Contacts
JOY ROACH
joy.roach@oncology.ox.ac.uk
01865 270000
NCITA CTU
ncita.fig@ucl.ac.uk
ClinicalTrials.gov
NCT04870580Drug / Compound
Help us improve your experience